Predictors of long-term drug survival for infliximab in psoriasis.

about

Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study.

P2860

Q40437510-7402C3E9-D4D7-4AAC-887B-794D5F1175F8

P2860

Predictors of long-term drug survival for infliximab in psoriasis.

Item

http://www.wikidata.org/entity/Q39668241

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Predictors of long-term drug survival for infliximab in psoriasis.

@en

Predictors of long-term drug survival for infliximab in psoriasis.

@nl

type

Item

label

Predictors of long-term drug survival for infliximab in psoriasis.

@en

Predictors of long-term drug survival for infliximab in psoriasis.

@nl

prefLabel

Predictors of long-term drug survival for infliximab in psoriasis.

@en

Predictors of long-term drug survival for infliximab in psoriasis.

@nl

P1476

Predictors of long-term drug survival for infliximab in psoriasis

@en

P2093

C Gaudy-Marqueste

http://www.w3.org/2001/XMLSchema#string

D Jullien

http://www.w3.org/2001/XMLSchema#string

E Delaporte

http://www.w3.org/2001/XMLSchema#string

E Karimova

http://www.w3.org/2001/XMLSchema#string

F Aubin

http://www.w3.org/2001/XMLSchema#string

F Guibal

http://www.w3.org/2001/XMLSchema#string

H Montaudié

http://www.w3.org/2001/XMLSchema#string

K Baumstark

http://www.w3.org/2001/XMLSchema#string

M Viguier

http://www.w3.org/2001/XMLSchema#string

M-A Richard

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis.

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

Clinical pharmacokinetics and use of infliximab.

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.

Optimizing anti-TNF treatments in inflammatory bowel disease.

Antidrug antibodies in psoriasis: a systematic review.

Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.

Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.

P304

96-101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDV.13747

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marie Beylot-Barry

Hervé Bachelez

P577

2016-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27325600

http://www.w3.org/2001/XMLSchema#string

Predictors of long-term drug survival for infliximab in psoriasis.

about

P2860

P2860

Predictors of long-term drug survival for infliximab in psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698